

- HIV infection, neoplastic disease in (*Cont.*):
 primary central nervous system lymphoma, 601
 primary effusion lymphoma, 135e-2
 neurologic disease in, **1263**, 1263t
 aseptic meningitis, 1264
 Chagas disease, 1265
 chronic meningitis, 907, 908t, 911
 cryptococcal meningitis, 1264, 1341
 distal sensory polyneuropathy, 1267, 2684
 focal neurologic deficits, 1265
 HIV-associated dementia, 1263, 1264t, 1265f
 HIV-associated neurocognitive disorders, 1241, 1263, 1264t, 1265f
 inflammatory demyelinating polyradiculoneuropathy, 2685
 meningitis, 892–893, 899
 mononeuropathies, 2685
 myelopathy, 1266–1267
 myopathy, 1266–1267
 pathogenesis of, 1241–1242, 1263–1264
 peripheral neuropathy, 1267, 2684–2685
 polyradiculopathy, 2685
 progressive multifocal leukoencephalopathy, 899–900, 1266
 seizures, 1265, 1265t
 sensory neuronopathy/ganglionopathy, 2685
 stroke, 1266
 toxoplasmosis, 1265–1266, 1266f, 1401–1402, 1402f
- ophthalmologic disease in, **1267**
 choroid lesions, 1267–1268
 CMV retinitis, 215e-7–8, 1192, 1267
 progressive outer retinal necrosis, 1267
 opportunistic/disseminated infections in actinomycosis, 1091
B. dermatitidis, 1338
Bartonella, 366, 1082, 1083f, 1268
 CMV, 1192, 1193
Cryptococcus, 1264, 1341
Cryptosporidium, 1407
Histoplasma, 1255, 1268
 incidence of, 1250, 1253f
 JC virus, 1266
Leishmania, 798, 1268, 1388, 1391
 malaria, 798, 1268, 1374
Nocardia, 1084
 nontuberculous mycobacterial, 1129
P. aeruginosa, 1047
P. marneffeii, 1268, 1354, 1354t
 prophylaxis for, 1251–1253t
T. cruzi, 1266
T. gondii, 1265–1266, 1266f, 1401–1402, 1402f, 1403, 1404, 1561
T. whipplei, 1091
- oropharyngeal disease in, 241t, **1255**
 aphthous ulcers, 237, 1255–1256, 1256f
 dysphagia, 257
 hairy leukoplakia, 1188, 1188f, 1255, 1256f
 linear gingival erythema, 236
 parotid enlargement, 241
 periodontitis, 236
 pharyngitis, 231
 during primary infection, 238t
 sicca syndrome, 2167t
 thrush, 1255, 1256f
 pathogenesis of, **1227**
 advanced disease, 1231
 apoptosis in, 1234
 autoimmune phenomenon in, 1234
 B cells defects in, 1237–1238
 CD4+ T cell defects in, 1236–1237
 CD8+ T cell defects in, 1237
 cellular targets, 1236
 chronic infection
 clinical latency vs. microbiologic latency, 1231
 immune system evasion, 1229–1230
 persistent virus replication, 1229, 1229f
 reservoirs of HIV-infected cells, 1230, 1230f
 viral dynamics, 1230–1231, 1231f
 clinical course in untreated patient, 1228f
 in CNS, 1241–1242
 cytokine network in, 1234–1235
 dendritic cell defects in, 1238
 immune activation, inflammation and, 1233–1234, 1233t
 in long-term nonprogressors, 1231–1232
 in long-term survivors, 1231–1232
 lymphocyte turnover in, 1235
 lymphoid organs and, 1232–1233, 1232f, 1233f
 macrophage defects in, 1238
 monocyte defects in, 1238
 NK cell defects in, 1238
 primary infection, 1228–1229, 1229f
 viral receptors and co-receptors in, 1234–1235, 1236f
- postexposure prophylaxis, 918, 1283
 in pregnancy, 50, 1223
 prevention of, 1284–1285
 renal disease in, 62e-1f, 1258–1259, 1849, 1864
- respiratory disease in, **1250**
 bacterial pneumonia, 1250
 fungal infections, 1254–1255
 MAC infections, 1251t, 1254
Pneumocystis pneumonia (PCP), 1250, 1251t, 1253, 1358, 1361
 pulmonary hypertension, 1255, 1658
R. equi infection, 1254
 tuberculosis. *See* Tuberculosis (TB), in HIV infection
- in returning war veterans, 152e-6t, 152e-8
 screening for, 24, 24f, 29t, 883, 1245, 1284–1285
- sepsis/septic shock in, 1757t
 skin manifestations of, **1262**
 bacillary angiomatosis, 365, 1082, 1083f, 1268
 condyloma acuminatum, 1263
 cutaneous drug reactions, 377, 384, 1263
 folliculitis, 1262–1263
 herpes zoster, 1185, 1185f, 1263
 HSV infections, 1263
 perirectal, 1257–1258, 1258f, 1263
 treatment of, 1181, 1182t, 1263
 ichthyosis, 1263
 molluscum contagiosum, 220e-1, 1263
 onychomycosis, 350
 in primary infection, 25e-2f, 127, 362, 362t
 psoriasis, 1263
 seborrheic dermatitis, 347, 1262
 skin cancer, 500
- stage 3. *See* AIDS
 staging, 1215–1216, 1216t
 symptomatic disease, **1250**
 thyroid hormone levels in, 2300
 transmission of
 in blood and blood products, 138e-3t, 138e-6, 735, 1220t, 1222–1223
 by breast-feeding, 50, 1223
 by human bite, 1220t, 1223
 mother-to-child, 50, 1223
 occupational, 1222–1223
 patterns, 1226–1227, 1226f
 prevention of, 1284–1285
 in saliva, 1220t, 1223
 sexual, 1220–1221, 1220t, 1221f
 traveler with, 798
- treatment of
 combination antiretroviral therapy. *See* Combination antiretroviral therapy (cART)
 with HCV co-infection, 2048–2049
 HSCT, 372e-31, 1239
 initial evaluation, 1272–1273, 1273t
 Internet resources for, 1273t
 milestones in, 771f
 in pregnancy, 50
 principles of, 1281–1283, 1282t
 vaccine development for, 1284
 weakness in, 156
 in women, 6e-2f, 6e-4
- H⁺,K⁺-ATPase, 372e-24t, 1913–1914
 HK (hexokinase) deficiency, 654t
 HLA-B gene, 1239, 1240t
 HLA-B8 gene mutations, 2346
 HLA-B locus, 38, 39t, 41, 373e-1, 373e-7, 378.
See also Human leukocyte antigen (HLA) complex
 HLA-C gene, 1240t, 1241
 HLA complex. *See* Human leukocyte antigen (HLA) complex
 HLA-DR3 gene mutations, 2323, 2346
 HLA-DR4, 2202
 HLA-DRB1 gene, 2139
 HMBS gene, 2523t
 HMBS gene mutations, 2526, 2529
 HMB synthase, 2523t, 2524
 hMG (human menopausal gonadotropin), 337
 HMG-CoA reductase inhibitors. *See* Statins
hMLH1 gene mutations, 539, 554
 HMPV (human metapneumovirus) infections, 1202t, 1206–1207
hMSH2 gene mutations, 539, 554
 HNF gene mutations, 431t, 2406
 HNPCC. *See* Hereditary nonpolyposis colon cancer (HNPCC)
 HNPP (hereditary neuropathy with liability to pressure palsies), 2678, 2679t
- Hoarseness
 with dysphagia, 256
 in GERD, 262
 in laryngeal cancer, 503
 in laryngitis, 234
 in lung cancer, 510
- Hockey puck sign, 1014
- Hodgkin's lymphoma, **708**
 approach to the patient, 700
 classical, 708–809
 classification of, 696t
 clinical features of, 708
 diagnosis of, 708–709
 EBV infection and, 214e-7, 697, 1189
 epidemiology of, 697
 fever in, 126
 infections in, 484t, 486t, 489
 lymphocyte-depleted, 708
 vs. mediastinal B-cell lymphoma, 135e-2
 mixed cellularity, 697, 708, 709f
 nodular lymphocyte-predominant, 709
 nodular sclerosing, 81e-11f, 697, 708
 paraneoplastic syndromes in, 612, 612t, 617, 618
 peripheral blood smear in, 81e-11f
 during pregnancy, 124e-1t, 124e-4
 radiation therapy for, breast cancer following, 103e-4, 524, 623
 second malignancies in survivors of, 623
 skin manifestations of, 366
 splenomegaly in, 410
 staging of, 413, 700, 701t, 709
 treatment of, 709
 brentuximab vedotin, 102e-4, 102e-5t, 103e-22
 HSCT, 139e-5t, 139e-6
 late consequences of, 623, 624t, 709, 2365
 tumor markers in, 473t
 “Holiday heart,” 2725
- Hollenhorst plaques, 40e-4, 201, 201f, 1443
- Holobiont, 86e-1, 86e-1t
- Holter monitoring, 273e-5
- Holt-Oram syndrome, 431t, 1443
- Homan's sign, 1443
- Home health care, 83, 83t
- Homeless, mental health problems in, 2723
- Homeopathy, 14e-1t, 14e-3
- Homeostasis, 400e-5
- Homer-Wright rosettes, 602
- Homocitrullinuria, 434e-3t, 435e-1t
- Homocysteine, 96e-4, 647
- Homocystinuria(s), **434e-1**
 cardiovascular disease in, 643
 classic, 434e-1
 clinical features of, 434e-2t, 434e-4
 enzyme defects in, 434e-2t
 folate deficiency in, 643, 647